PEX16

Across TCGA pan-cancer cohorts, PEX16 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PEX16 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PEX16 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PEX16 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where PEX16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.202	0.985	.007	16	view →
HNSC	OS	Median	II,III,IV	0.855	0.607	.002	16	view →
PDAC	DFS	Median	IV	0.245	0.715	.038	3	view →
LSCC	OS	Quartile	III,IV	0.901	0.441	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PEX16–CCRCC (OS)

Open the CCRCC breakdown →